TIDMDEST

RNS Number : 4997I

Destiny Pharma PLC

22 March 2018

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Appointment of Joint Broker

Brighton, United Kingdom - 22 March 2018 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), today announces the appointment of finnCap Ltd as joint broker to the Company with immediate effect. Cantor Fitzgerald Europe remains nominated adviser and joint broker to the Company.

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Simon Sacerdoti, CFO

pressoffice@destinypharma.com

+44 (0)1273 704 440

FTI Consulting

Simon Conway / Victoria Foster Mitchell

destinypharma@fticonsulting.com

+44 (0) 20 3727 1000

Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker)

Philip Davies / Will Goode, Corporate Finance

Andrew Keith, Healthcare Equity Sales

+44 (0)20 7894 7000

finnCap Ltd (Joint Broker)

Geoff Nash /Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

+44 (0)20 7220 0500

About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the WHO and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPQFLFLVXFBBBQ

(END) Dow Jones Newswires

March 22, 2018 03:02 ET (07:02 GMT)

Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Destiny Pharma Charts.
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Destiny Pharma Charts.